Trial · NCT02917187
A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
NCT02917187, Phase 2, Completed, Biogen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia. Trials, record NCT02917187. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02917187
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
- NCT number
- NCT02917187
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- Biogen
- Conditions
- Primary Inherited Erythromelalgia
- Interventions
- BIIB074, Placebo
- First posted
- 2016-09-28
- Last updated
- 2018-01-10
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weekly average severity of paroxysms | Day 1 to Week 12 | 11-point Pain Intensity Numerical Rating Scale (PI-NRS) is used to assess EM paroxysmal pain. PI-NRS is an 11-point pain intensity numerical rating scale, where 0=no pain and 10=worst possible pain. Weekly average is defined as the total of severity scores during a week divided by the total number of paroxysms during that week. |
| Secondary | Weekly maximum severity of paroxysms | Day 1 to Week 12 | The weekly maximum severity is the maximum paroxysm severity recorded by a participant in a given week. |
| Secondary | Weekly average and maximum number of paroxysms | Day 1 to Week 12 | |
| Secondary | Weekly average and weekly maximum duration of paroxysms | Day 1 to Week 12 | |
| Secondary | Weekly average and weekly maximum of daily background pain | Day 1 to Week 12 | Each participant provides a daily background pain score via a diary that records background daily pain intensity using a numerical rating scale from 0-10 with higher scores indicating worse pain. |
| Secondary | Patient Global Impression of Change (PGIC) score | Day 1 to Week 12 | PGIC is a 7-point self-report scale depicting a participant's rating of overall improvement. Participants rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." |
| Secondary | Weekly average and weekly maximum number of pain-mitigating activities | Day 1 to Week 12 | Participant diary is used to record pain mitigating cooling activities that include but are not limited to use of cold water or fan. |
| Secondary | Weekly average and weekly maximum duration of pain-mitigating activities | Day 1 to Week 12 | Participant diary is used to record pain mitigating activities that include but are not limited to use of cooling, and breathing/relaxation and mental imagery techniques. |
| Secondary | Use of rescue medication | Day 1 to Week 13 | |
| Secondary | Weekly average and weekly maximum of the daily sleep interference scale | Day 1 to Week 12 | Daily Sleep Interference Scale (DSIS) describes how much EM pain interfered with the participant's sleep with 0 indicating "pain did not interfere with sleep" and 10 indicating "pain completely interfered with sleep". |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02917187
GET https://conductscience.org/api/trials/v1/NCT02917187/registered